JAKARTA – A pharmaceutical company, PT Pyridam Farma Tbk (PYFA), through its subsidiary, PT Ethica Industri Farmasi (EIF), managed to secure IDR 120 billion loan from PT Bank Mandiri (Persero) Tbk (BMRI).

On January 31, 2025, EIF and BMRI officially signed Investment Credit Agreement II No. 58. “EIF will receive new loan in the form of Credit Investment 2 with limit set to IDR 120 billion,” said Herdiasti Anggitya Dwisani, Corporate Secretary of PYFA, in the information disclosure in Indonesia Stock Exchange (IDX), Monday (3/2).

Based on said agreement, the interest rate is set to 8.25% per annum, with repayment period of 96 months from the signing date.

Dwisani further said that the facility will be used for refinancing EIF’s existing assets in the form of land and building of Jababeka Industrial Area, Central Cikrang, Bekasi, West Java.

In addition to credit agreement, EIF also signed the Addendum to the Cross Default and Cross Collateral Agreement No. 59, as well as the Power of Attorney to Encumber Mortgage Rights No. 60, as well as other supporting documents.

PYFA ensures there will be no material impact on the company’s operations, legal standing, or business continuity as a result of this transaction, except for the obligation to pay loan interest and principal periodically.

At the morning session today (3/2), at 10 AM WIB, PYFA already booked 3.39% slippage compared to the opening price, from IDR 236 to IDR 228 per share. (DK/ZH)